Acetyl Angiotensinogen (1-14), Porcine Mechanisms, Clinical

Acetyl Angiotensinogen (1-14), Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Acetyl Angiotensinogen (1-14), porcine, is a synthetic peptide derivative of the angiotensinogen protein, specifically comprising the first 14 amino acids of the porcine angiotensinogen sequence with an acetyl modification at the N-terminus. Angiotensinogen, a precursor in the renin-angiotensin system (RAS), plays a pivotal role in the regulation of blood pressure, fluid balance, and electrolyte homeostasis (Paul et al., 2006, Hypertension). The acetylation of the N-terminus is hypothesized to enhance peptide stability and bioavailability, making Acetyl Angiotensinogen (1-14) a valuable research tool for dissecting the early molecular events in RAS signaling.

Mechanistically, Acetyl Angiotensinogen (1-14) serves as a substrate for renin, which cleaves it to generate angiotensin I, subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is a potent vasoconstrictor, implicated in hypertension, cardiovascular remodeling, and renal pathophysiology (Fyhrquist & Saijonmaa, 2008, J Intern Med). The synthetic peptide allows researchers to study the initial steps of the RAS cascade in vitro and in vivo, providing insights into the modulation of angiotensinogen processing and the downstream physiological effects.

Clinical Value and Applications
The clinical value of Acetyl Angiotensinogen (1-14), porcine, lies primarily in its utility as a research reagent for elucidating the molecular mechanisms of RAS-related disorders, including hypertension, heart failure, chronic kidney disease, and metabolic syndrome. By offering a defined substrate for renin, this peptide enables precise quantification of renin activity, ACE function, and angiotensin II generation in experimental systems (Campbell, 2017, Pharmacol Res).

In preclinical models, Acetyl Angiotensinogen (1-14) has been used to investigate the efficacy of RAS inhibitors, such as ACE inhibitors and angiotensin receptor blockers (ARBs), by providing a controlled substrate for pharmacodynamic studies (Bader & Ganten, 2008, Circ Res). Furthermore, its application extends to the study of novel RAS modulators, including neprilysin inhibitors and direct renin inhibitors, facilitating the development of next-generation antihypertensive therapies.

The peptide’s acetylation confers increased resistance to proteolytic degradation, making it suitable for in vitro assays and in vivo studies where peptide stability is critical. This property is particularly advantageous in the context of high-throughput screening of RAS-targeted compounds and in the assessment of renin activity in biological samples (Kokubo et al., 2019, Peptides).

[Related: aprotinin inhibitor] Key Challenges and Pain Points Addressed
Traditional approaches to studying the RAS have relied on native angiotensinogen or longer peptide fragments, which are often susceptible to rapid degradation by endogenous proteases, leading to inconsistent results and limited reproducibility (Paul et al., 2006, Hypertension). Acetyl Angiotensinogen (1-14), porcine, addresses these challenges by providing a chemically defined, stable substrate that mimics the physiological precursor of angiotensin I.

Another significant pain point in RAS research is the variability in renin activity assays due to differences in substrate quality and purity. The synthetic nature of Acetyl Angiotensinogen (1-14) ensures batch-to-batch consistency, enabling reliable quantification of enzymatic activity and facilitating cross-laboratory comparisons (Campbell, 2017, Pharmacol Res).

Moreover, the peptide’s resistance to non-specific proteolysis reduces background noise in experimental assays, improving signal-to-noise ratios and enhancing the sensitivity of detection methods. This is particularly important in the context of low-abundance enzyme measurements and in studies involving complex biological matrices (Kokubo et al., 2019, Peptides).

Literature Review
A growing body of literature supports the use of synthetic angiotensinogen peptides in RAS research. Paul et al. (2006, Hypertension) highlighted the importance of angiotensinogen-derived peptides in understanding the regulation of blood pressure and the pathogenesis of hypertension. Their work demonstrated that truncated angiotensinogen fragments can serve as effective substrates for renin, enabling detailed kinetic analyses.

Fyhrquist and Saijonmaa (2008, J Intern Med) reviewed the central role of the RAS in cardiovascular and renal diseases, emphasizing the need for robust experimental tools to dissect the system’s complexity. They noted that synthetic peptides, such as Acetyl Angiotensinogen (1-14), are instrumental in studying the enzymatic steps leading to angiotensin II formation.

Campbell (2017, Pharmacol Res) discussed advances in RAS research methodologies, including the use of modified peptides for renin and ACE assays. The author underscored the value of acetylated substrates in improving assay specificity and reproducibility.

Bader and Ganten (2008, Circ Res) explored the therapeutic implications of RAS modulation, highlighting the need for precise experimental models to evaluate the effects of pharmacological agents. Their review cited the use of synthetic angiotensinogen peptides in preclinical drug development.

Kokubo et al. (2019, Peptides) provided experimental evidence for the enhanced stability of acetylated angiotensinogen fragments, demonstrating their utility in both in vitro and in vivo studies. The authors reported that acetylation significantly reduces proteolytic degradation, extending the peptide’s half-life in biological systems.

In a study by Matsusaka et al. (2014, J Am Soc Nephrol), the authors used synthetic angiotensinogen peptides to investigate the tissue-specific regulation of RAS components in kidney disease models. Their findings underscored the importance of substrate selection in accurately assessing renin activity.

Finally, a review by Danser and Deinum (2005, J Hypertens) discussed the challenges of measuring renin and angiotensinogen activity in clinical and experimental settings, advocating for the use of standardized synthetic substrates to improve assay reliability.

[Related: olaparib cost] Experimental Data and Results
Experimental studies utilizing Acetyl Angiotensinogen (1-14), porcine, have demonstrated its effectiveness as a substrate for renin activity assays. In vitro experiments have shown that the acetylated peptide is efficiently cleaved by renin to produce angiotensin I, with kinetic parameters comparable to those observed with native angiotensinogen (Kokubo et al., 2019, Peptides). The acetyl modification does not interfere with renin recognition or cleavage, ensuring physiological relevance.

Stability assays indicate that Acetyl Angiotensinogen (1-14) exhibits a significantly prolonged half-life in plasma and tissue homogenates compared to non-acetylated counterparts. This enhanced stability translates to improved assay performance, with reduced background degradation and increased signal specificity (Kokubo et al., 2019, Peptides).

In animal models, administration of Acetyl Angiotensinogen (1-14) has been used to monitor in vivo renin activity and to evaluate the pharmacodynamic effects of RAS inhibitors. For example, in hypertensive rat models, the peptide enabled precise quantification of renin inhibition following ACE inhibitor treatment, correlating with reductions in blood pressure and angiotensin II levels (Bader & Ganten, 2008, Circ Res).

Furthermore, high-throughput screening assays employing Acetyl Angiotensinogen (1-14) have facilitated the identification of novel renin inhibitors, with improved assay robustness and reproducibility compared to traditional substrates (Campbell, 2017, Pharmacol Res).

Usage Guidelines and Best Practices
For optimal results, Acetyl Angiotensinogen (1-14), porcine, should be handled and stored according to standard peptide protocols. The lyophilized peptide should be reconstituted in sterile, deionized water or appropriate buffer (e.g., phosphate-buffered saline, pH 7.4) to the desired concentration, typically ranging from 10 μM to 1 mM depending on the assay requirements.

Aliquots should be stored at -20°C or below to prevent repeated freeze-thaw cycles, which may compromise peptide integrity. For in vitro assays, the peptide can be used as a substrate in renin activity assays, ACE assays, or in studies of angiotensinogen processing. It is recommended to include protease inhibitors in assay buffers to minimize non-specific degradation, although the acetyl modification provides inherent stability.

In in vivo studies, dosing should be based on preliminary pharmacokinetic and toxicity assessments, with careful monitoring of physiological parameters. The peptide’s stability allows for extended circulation times, but dose optimization is essential to avoid off-target effects.

Quality control measures, including mass spectrometry and HPLC analysis, should be employed to verify peptide purity and identity prior to use. Batch-to [Related: suramin sodium salt] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 53 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11533975